Skip to content Skip to sidebar Skip to footer

Novo Nordisk

Diabeloop teams up with Novo Nordisk on next-generation insulin pens

Diabeloop SA reported a partnership with Novo Nordisk A/S. The med-tech is planning to integrate DBL-4pen, its self-learning algorithm for multiple daily injection therapy, into Novo Nordisk's connected, reusable insulin pens: Novopen and Novopen Echo Plus. “Our partnership is designed to deliver more automated solutions to people with diabetes, optimizing outcomes and improving quality of…

Read More

Health News Roundup: Nvidia deepens bets on AI in drug discovery with Recursion investment; US FDA reviewing concerns over Logan Paul’s PRIME energy drink and more

Following is a summary of current health news briefs. Nvidia deepens bets on AI in drug discovery with Recursion investment Chip designer Nvidia will invest $50 million to speed up training of Recursion's artificial intelligence models for drug discovery, the companies said on Wednesday, sending the biotech firm's shares surging about…

Read More

The increasing need for AI in the pharma industry

By Meena Villa Vij, Vice President, Digital, Data & IT, Novo Nordisk Global Business Services and Francis Prashanth Anandan, Lead, Digital Innovation Hub, India, Novo Nordisk Global Business Services The pharmaceutical industry has been on an accelerated path to scientific advancement. A human-centric approach to drug discovery combined with core competencies and technology platforms drive…

Read More

Novo Nordisk to support MIT postdocs working at the intersection of AI and life sciences | MIT News

MIT’s School of Engineering and global health care company Novo Nordisk has announced the launch of a multi-year program to support postdoctoral fellows conducting research at the intersection of artificial intelligence and data science with life sciences. The MIT-Novo Nordisk Artificial Intelligence Postdoctoral Fellows Program will welcome its first cohort of up to 10 postdocs…

Read More

Policy and Medicine Compliance Update May 2023 Issue Features: Regulatory Challenges in Diversity in Clinical Trials, Embracing Generative Artificial Intelligence, Novo Nordisk’s Trans-Atlantic Speech Woes, and The Sixth Circuit Tackles the Meaning of Remuneration in Kickback Cases

Policy and Medicine Compliance Update is our monthly compliance publication designed to help compliance professionals go in depth in issues and stay up to date on the latest trends.   We encourage you to subscribe to our monthly publication Policy an

Read More